This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialysis. In Order to Evaluate the Need of Adjuvant Uric Acid Lowering Therapy

NCT07144332 | Recruiting

• 1 other identifier: Soh-Med-25-7-13MS
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Background: Uricemia dramatically rises with the stage of chronic kidney disease (CKD) and correlates with its mortality. Hemodialysis (HD) being the most used treatment at the end stage kidney disease in Sohag governorate , we sought to evaluate its efficacy on the clearance of uric acid (UAc) when used alone and twice per week. Methods: A cross-sectional study of all consenting patients with CKD stage 5 recruited at random during hemodialysis sessions at hemodialysis unit in Sohag university hospital from July to December 2025. We collected socio-demographic data, relevant clinical information, hemodialysis related variables, and measured serum uric acid (SUA) levels before and after the dialysis to assess the uric acid clearance. A clearance between 65 and 80% and above 80% was considered as low and good efficacy of hemodialysis respectively

Conditions

Hemodialysis; Hyperuricemia

Keywords

Hemodialysis; Hyperuricemia; chronic kidney disease

Outcome Measures

Primary Outcomes (1)

• study of serum uric acid level in hemodialysis patients

  milligrams per deciliter (mg/dL)

  during hemodialysis session 2 to 3 hours

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Hemodialysis patients

You may qualify if:

• We included all consenting adults aged 18 or older, on maintenance hemodialysis for at least 3 consecutive months receiving 2 to 3 sessions weekly

You may not qualify if:

• Patients aged \< 18 years old .
• Patients on recent hemodialysis less than 3 months.
• We excluded patients who were on Uric acid lowering therapy (UALT).
• Patients received less than 4 hours of hemodialysis and those who had emergency dialysis.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Sohag university faculty of medicine

Sohag, Egypt

RECRUITING

MeSH Terms

Conditions

Hyperuricemia; Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes

Central Study Contacts

Reham Hussien, master

CONTACT

00201092162739; rehamhussien1937@yahoo.com

Ali taha, Professor

CONTACT

00201005871047

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Internal medicine resident doctor

Study Record Dates

• First Submitted: August 20, 2025
• First Posted: August 27, 2025
• Study Start: July 13, 2025
• Primary Completion: December 29, 2025
• Study Completion: February 1, 2026
• Last Updated: August 27, 2025

Record last verified: 2025-08

Locations

EG (1)